6med - Revision history

OCA at 06:29, 11 October 2023

OCA — Wed, 11 Oct 2023 06:29:54 GMT

←Older revision		Revision as of 06:29, 11 October 2023
Line 3:		Line 3:
	<StructureSection load='6med' size='340' side='right'caption='[[6med]], [[Resolution\|resolution]] 2.04Å' scene=''>		<StructureSection load='6med' size='340' side='right'caption='[[6med]], [[Resolution\|resolution]] 2.04Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6med]] is a 6 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MED OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6MED FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6med]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MED OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MED FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.04Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6med FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6med OCA], [~~http~~://pdbe.org/6med PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6med RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6med PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6med ProSAT]</span></td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6med FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6med OCA], [https://pdbe.org/6med PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6med RCSB], [https://www.ebi.ac.uk/pdbsum/6med PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6med ProSAT]</span></td></tr>
	</table>		</table>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
Line 18:		Line 19:

	==See Also==		==See Also==
-	*[[~~Antibody~~ 3D structures\|~~Antibody~~ 3D structures]]	+	*[[Monoclonal Antibodies 3D structures\|Monoclonal Antibodies 3D structures]]
		+	*[[Sandbox 20009\|Sandbox 20009]]
		+	*[[3D structures of human antibody\|3D structures of human antibody]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Bjorkman~~, P J~~]]	+	[[Category: Bjorkman PJ]]
-	[[Category: Flyak~~, A I]]~~	+	[[Category: Flyak AI]]
-	~~[[Category: Broadly neutralizing antibody]]~~	+
-	~~[[Category: Hcv glycoprotein]]~~	+
-	~~[[Category: Immune system~~]]	+

OCA at 08:23, 6 November 2019

OCA — Wed, 06 Nov 2019 08:23:53 GMT

←Older revision		Revision as of 08:23, 6 November 2019
Line 1:		Line 1:

-	==~~Broadly~~ neutralizing ~~antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design~~==	+	==Crystal structure of broadly neutralizing antibody HEPC3==
-	<StructureSection load='6med' size='340' side='right' caption='[[6med]], [[Resolution\|resolution]] 2.04Å' scene=''>	+	<StructureSection load='6med' size='340' side='right'caption='[[6med]], [[Resolution\|resolution]] 2.04Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6med]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MED OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MED FirstGlance]. <br>		<table><tr><td colspan='2'>[[6med]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MED OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MED FirstGlance]. <br>
Line 16:		Line 16:
	</div>		</div>
	<div class="pdbe-citations 6med" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6med" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 21:		Line 24:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Bjorkman, P J]]		[[Category: Bjorkman, P J]]
	[[Category: Flyak, A I]]		[[Category: Flyak, A I]]

OCA at 21:09, 2 December 2018

OCA — Sun, 02 Dec 2018 21:09:10 GMT

←Older revision		Revision as of 21:09, 2 December 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6med is ~~ON HOLD until Paper~~ Publication	+	==Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design==
		+	<StructureSection load='6med' size='340' side='right' caption='[[6med]], [[Resolution\|resolution]] 2.04Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6med]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MED OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MED FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6med FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6med OCA], [http://pdbe.org/6med PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6med RCSB], [http://www.ebi.ac.uk/pdbsum/6med PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6med ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Hepatitis C virus (HCV) vaccine efforts are hampered by the extensive genetic diversity of HCV envelope glycoproteins E1 and E2. Structures of broadly neutralizing antibodies (bNAbs) (e.g., HEPC3, HEPC74) isolated from individuals who spontaneously cleared HCV infection facilitate immunogen design to elicit antibodies against multiple HCV variants. However, challenges in expressing HCV glycoproteins previously limited bNAb-HCV structures to complexes with truncated E2 cores. Here we describe crystal structures of full-length E2 ectodomain complexes with HEPC3 and HEPC74, revealing lock-and-key antibody-antigen interactions, E2 regions (including a target of immunogen design) that were truncated or disordered in E2 cores, and an antibody CDRH3 disulfide motif that exhibits common interactions with a conserved epitope despite different bNAb-E2 binding orientations. The structures display unusual features relevant to common genetic signatures of HCV bNAbs and demonstrate extraordinary plasticity in antibody-antigen interactions. In addition, E2 variants that bind HEPC3/HEPC74-like germline precursors may represent candidate vaccine immunogens.

-	~~Authors:~~ Flyak, ~~A.I.~~, ~~Bjorkman~~, P.J.	+	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.,Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009. PMID:30439340<ref>PMID:30439340</ref>

-	~~Description: Broadly neutralizing antibodies against HCV use~~ a ~~CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: Bjorkman, P.J]]	+	<div class="pdbe-citations 6med" style="background-color:#fffaf0;"></div>
-	[[Category: Flyak, A.I]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Bjorkman, P J]]
		+	[[Category: Flyak, A I]]
		+	[[Category: Broadly neutralizing antibody]]
		+	[[Category: Hcv glycoprotein]]
		+	[[Category: Immune system]]

OCA at 06:27, 26 September 2018

OCA — Wed, 26 Sep 2018 06:27:28 GMT

←Older revision		Revision as of 06:27, 26 September 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6med is ON HOLD	+	The entry 6med is ON HOLD until Paper Publication

	Authors: Flyak, A.I., Bjorkman, P.J.		Authors: Flyak, A.I., Bjorkman, P.J.

OCA: Protected "6med" [edit=sysop:move=sysop]

OCA — Wed, 12 Sep 2018 06:18:31 GMT

Protected "6med" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:18, 12 September 2018

OCA: New page: '''Unreleased structure''' The entry 6med is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

OCA — Wed, 12 Sep 2018 06:18:29 GMT

New page: '''Unreleased structure''' The entry 6med is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

New page

'''Unreleased structure'''

The entry 6med is ON HOLD

Authors: Flyak, A.I., Bjorkman, P.J.

Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design
[[Category: Unreleased Structures]]
[[Category: Bjorkman, P.J]]
[[Category: Flyak, A.I]]